CompletedNot Applicable

Appropriate Medication Use in Dutch Terminal Care

Netherlands250 participantsStarted 2022-04-29

Plain-language summary

The AMUSE trial is a multicentre stepped-wedge cluster randomized controlled trial where medication optimization of patients with a life expectancy of less than three months is investigated by using CDSS-OPTIMED (a personalized medication advice to attending physicians of patients in the last phase of life) The investigators will include 250 patients, in 7 different study sites across the Netherlands. The primary outcome is an assessment of the quality of life of patients, two weeks after baseline assessment.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient is 18 years or older and provides informed consent to participate. * The patient is aware that recovering from his/her disease is unlikely, to be assessed by the attending physician. * The patient is competent to decide about trial participation * The patient has a life expectancy of at least two weeks and at most three months, as estimated by an attending physician. Exclusion Criteria: * The patient is incapable of filling in a questionnaire (patients may be supported by relatives when filling in the questionnaire).

What they're measuring

Patients' quality of life

Timeframe: Two weeks after baseline assessment

Trial details

NCT IDNCT05351281

SponsorProf.dr Carin (C.C.D.) van der Rijt

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-10-16

View on ClinicalTrials.gov More Palliative Care trials